The Effects of Dietary Supplementation on Serum Protein Glycosylation

Sponsor
University of California, Davis (Other)
Overall Status
Recruiting
CT.gov ID
NCT05040204
Collaborator
National Institutes of Health (NIH) (NIH), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) (NIH)
44
1
5
10
4.4

Study Details

Study Description

Brief Summary

Two randomized double-blind placebo-controlled clinical studies to assess the effects of dietary glycan monomer supplementation on the immune system, especially antibody glycosylation in healthy adults. Immune profiling and glycoproteomics will be performed on serum isolated at these same time points.

Condition or Disease Intervention/Treatment Phase
  • Dietary Supplement: Monosaccharide Powder
  • Dietary Supplement: Placebo Comparator
Phase 1

Study Design

Study Type:
Interventional
Anticipated Enrollment :
44 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Participant, Investigator)
Primary Purpose:
Basic Science
Official Title:
The Effects of Dietary Supplementation on Serum Protein Glycosylation
Anticipated Study Start Date :
Jan 1, 2023
Anticipated Primary Completion Date :
Nov 1, 2023
Anticipated Study Completion Date :
Nov 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Experimental Supplement 1

6 subjects will consume 12 grams of dietary supplement 1 daily for 4 weeks

Dietary Supplement: Monosaccharide Powder
Monosaccharide powder dissolved in water.

Experimental: Experimental Supplement 2

6 subjects will consume 12 grams of dietary supplement 2 daily for 4 weeks

Dietary Supplement: Monosaccharide Powder
Monosaccharide powder dissolved in water.

Experimental: Experimental Supplement 3

20 subjects will consume 50 grams of dietary supplement 3 daily for 4 weeks

Dietary Supplement: Monosaccharide Powder
Monosaccharide powder dissolved in water.

Placebo Comparator: Placebo Comparator 1

6 subjects will consume 12 grams of placebo dietary supplement daily for 4 weeks

Dietary Supplement: Placebo Comparator
Placebo (glucose powder)

Placebo Comparator: Placebo Comparator 2

6 subjects will consume 50 grams of placebo dietary supplement daily for 4 weeks

Dietary Supplement: Placebo Comparator
Placebo (glucose powder)

Outcome Measures

Primary Outcome Measures

  1. Characterize Immunoglobulin fragment crystallization modifications [4 Weeks]

    Use mass spectrometry and RNA sequencing from subject blood samples to characterize site specific glycosylation on Immunoglobulin A, Immunoglobulin M, and Immunoglobulin G.

Secondary Outcome Measures

  1. Assess for potential adverse events [2 months after first dose]

    Monitor symptoms, severity, and duration of adverse events.

  2. Quantification of enzymatic modifications measured in grams by spectrometry [6 months]

    The investigators will measure enzymatic changes on glycoproteins in the immune system by spectrometry, i.e., these changes will be measured in grams. Spectometry will allow the investigators to quantify these changes in small detail, and therefore give a better idea of how supplementation can change enzymatic process that then affect the structure, and mass, of glycoproteins.

  3. Flow cytometry to determine the effect of dietary supplementation on the immune system [6 months]

    Perform flow cytometry on subject blood samples to determine the effect of dietary supplement on immune system. For example, the investigators will note changes to immune cell pro-inflammatory and anti-inflammatory cytokine clusters as translated proteins (measured as height and area of cytokine intensity).

  4. Transcriptome analysis to determine the effect of dietary supplementation on the immune system [6 months]

    Perform transcriptome analysis on subject blood samples to determine the effect of dietary supplement on immune system. For example, the investigators will note changes to immune cell pro-inflammatory and anti-inflammatory cytokine clusters as RNA (measure on a logarithmic scale per number of reads) to determine the effects of supplementation on both gene transcription and translation.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 45 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Adult men/women (age 18-45) who are in general good health with Body Mass Index (BMI) range of 18.5-25
Exclusion Criteria:
  • Adults younger than 18 or older than 45 years of age

  • Women who are pregnant, actively nursing or have had a pregnancy within the last year

  • Women who are peri-menopausal or post-menopausal

  • Women with irregular menstrual cycles (more frequently than every 21 days or lasts longer than 8 days. Missed, early, or late periods are also considered signs of an irregular cycle)

  • Women on hormonal contraception, including birth control, hormonal intrauterine device, or contraceptive implant

  • Individuals with past medical history of an autoimmune condition or malignancy, excluding non-melanoma skin cancer

  • Individuals with cardiovascular, pulmonary, reproductive, endocrine, metabolic, neurologic, gastrointestinal, hematologic, or infectious diseases of any type

  • Individuals with diagnosis of galactosemia or congenital disorders of glycosylation

  • Individuals with phenylketonuria

  • Individuals currently taking prescription medications, or who have taken prescription medications within the last 3 months

  • Individuals currently taking over-the-counter medications

  • Individuals currently taking or who have taken supplements including herbal, protein or vitamin supplements in the last 3 months (e.g. whey protein, St. John's Wort, green tea supplements, biotin, creatine supplements), excluding multivitamins or essential vitamins

  • Individuals with BMI less than 18.5 or greater than 25

  • Individuals with prior history of severe food or drug allergic reactions

  • Individuals with allergic reaction or adverse reaction to shellfish, N-acetylglucosamine, galactose, Spirulina/chlorella/algae supplements, or arabinose containing compounds/foods/supplements

  • Individuals with first-degree relative with history of an autoimmune condition

  • Individuals with social history of current use of tobacco, alcohol or other drugs

  • Individuals with dietary restrictions (vegetarians are permitted to participate in the study) or atypical exercise patterns, or to whom any of the following dietary habits or characteristics apply (the following exclusion criteria are placed to minimize variability in diet/exercise patterns in our pilot study population):

  • Actively dieting or trying to lose weight

  • Vegan diet

  • Consume equal to or greater than 2 cups of tea a day

  • Consume equal to or greater than 4 cups of coffee a day

  • Consume equal to or greater than 3 cups of fruit juice a day

  • Practice intensive exercise patterns (marathon training, workouts >4 hours a day)

  • Consume soda or energy drinks of any amount

  • Consume fast food equal to or greater than 5 days per week

  • Consume greater than one serving of alcohol per day

  • (1 serving of wine = 6 oz, 1 serving of beer = 12 oz, 1 serving of spirits = 1 oz)

  • On a carbohydrate-restricted or "Paleo" diet, or calorie-restricted diet (less than 20-25% of maintenance calories)

  • Adults unable to consent

  • Prisoners

Contacts and Locations

Locations

Site City State Country Postal Code
1 University of California, Davis Medical Center Sacramento California United States 95816

Sponsors and Collaborators

  • University of California, Davis
  • National Institutes of Health (NIH)
  • National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

Investigators

  • Principal Investigator: Emanual Maverakis, MD, University of California, Davis

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

Publications

None provided.
Responsible Party:
Emanual Maverakis, MD, Professor, University of California, Davis
ClinicalTrials.gov Identifier:
NCT05040204
Other Study ID Numbers:
  • 949221
  • 1K24AR077313-01A1
First Posted:
Sep 10, 2021
Last Update Posted:
May 5, 2022
Last Verified:
May 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Emanual Maverakis, MD, Professor, University of California, Davis

Study Results

No Results Posted as of May 5, 2022